prostate-specific membrane antigen

You have access
¹⁷⁷Lu-PSMA for Extended Treatment of Metastatic Castration-Resistant Prostate Cancer
Thorsten Derlin, Liam Widjaja, Rudolf A. Werner and Frank M. Bengel

Journal of Nuclear Medicine January 1, 2023, 64 (1) 54-58; DOI: https://doi.org/10.2967/jnumed.122.264293
You have access
Validation of ¹⁸F-rhPSMA-7 and ¹⁸F-rhPSMA-7.3 PET Imaging Results with Histopathology from Salvage Surgery in Patients with Biochemical Recurrence of Prostate Cancer
Markus Kroenke, Lilit Schweiger, Thomas Horn, Bernhard Haller, Kristina Schwamborn, Alexander Wurzer, Tobias Maurer, Hans-Jürgen Wester, Matthias Eiber and Isabel Rauscher

Journal of Nuclear Medicine December 1, 2022, 63 (12) 1809-1814; DOI: https://doi.org/10.2967/jnumed.121.263707
You have access
The PRIMARY Score: Using Intraprostatic ⁶⁸Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis
Louise Emmett, Nathan Papa, James Buteau, Bao Ho, Victor Liu, Matthew Roberts, James Thompson, Dan Moon, Gemma Sheehan-Dare, Omar Alghazo, Shikha Agrawal, Declan Murphy, Phillip Stricker, Thomas A. Hope and Michael S. Hofman

Journal of Nuclear Medicine November 1, 2022, 63 (11) 1644-1650; DOI: https://doi.org/10.2967/jnumed.121.263448
You have access
Robot-Assisted Prostate-Specific Membrane Antigen–Radioguided Surgery in Primary Diagnosed Prostate Cancer
William Gondoputro, Matthijs J. Scheltema, Alexander Blazevski, Paul Doan, James E. Thompson, Amer Amin, Bart Geboers, Shikha Agrawal, Amila Siriwardana, Pim J. Van Leeuwen, Matthias N. van Oosterom, Fijs W.B. Van Leeuwen, Louise Emmett and Phillip D. Stricker

Journal of Nuclear Medicine November 1, 2022, 63 (11) 1659-1664; DOI: https://doi.org/10.2967/jnumed.121.263743
You have access
Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
Christiane Schuchardt, Jingjing Zhang, Harshad R. Kulkarni, Xiaoyuan Chen, Dirk Müller and Richard P. Baum

Journal of Nuclear Medicine August 1, 2022, 63 (8) 1199-1207; DOI: https://doi.org/10.2967/jnumed.121.262713
You have access
¹⁸F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study
Harun Ilhan, Markus Kroenke, Alexander Wurzer, Marcus Unterrainer, Matthias Heck, Claus Belka, Karina Knorr, Thomas Langbein, Isabel Rauscher, Nina-Sophie Schmidt-Hegemann, Kilian Schiller, Peter Bartenstein, Hans-Jürgen Wester and Matthias Eiber

Journal of Nuclear Medicine August 1, 2022, 63 (8) 1208-1214; DOI: https://doi.org/10.2967/jnumed.121.262861
You have access
Effects of ²²⁵Ac-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis
Dong Yun Lee and Yong-il Kim

Journal of Nuclear Medicine June 1, 2022, 63 (6) 840-846; DOI: https://doi.org/10.2967/jnumed.121.262017
You have access
A Comprehensive Assessment of ⁶⁸Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients
Monica Abghari-Gerst, Wesley R. Armstrong, Kathleen Nguyen, Jeremie Calais, Johannes Czernin, David Lin, Namasvi Jariwala, Melissa Rodnick, Thomas A. Hope, Jason Hearn, Jeffrey S. Montgomery, Ajjai Alva, Zachery R. Reichert, Daniel E. Spratt, Timothy D. Johnson, Peter J.H. Scott and Morand Piert

Journal of Nuclear Medicine April 1, 2022, 63 (4) 567-572; DOI: https://doi.org/10.2967/jnumed.121.262412
You have access
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy
Liang Dong, Yun Su, Yinjie Zhu, Mark C. Markowski, Mei Xin, Michael A. Gorin, Baijun Dong, Jiahua Pan, Martin G. Pomper, Jianjun Liu, Kenneth J. Pienta, Wei Xue and Steven P. Rowe

Journal of Nuclear Medicine February 1, 2022, 63 (2) 248-252; DOI: https://doi.org/10.2967/jnumed.121.262411
You have access
Kidney Doses in ¹⁷⁷Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?
Michael Mix, Tobias Renaud, Felix Kind, Ursula Nemer, Elham Yousetzadeh-Nowsha, Tumelo C.G. Moalosi, Aymen M. Ormrane, Philipp T. Meyer and Juri Ruf

Journal of Nuclear Medicine February 1, 2022, 63 (2) 253-258; DOI: https://doi.org/10.2967/jnumed.121.262245

Main menu

User menu

Search

prostate-specific membrane antigen

Pages